SABS News and Press, SAB Biotherapeutics Inc. From 03/02/22

SAB Biotherapeutics (NASDAQ:SABS) said the National Institutes of Health (NIH) is closing enrollment in its ACTIV-2 trial due to low Omicron-related COVID-19 hospitalization and death rates that have made the current study design statistically unworkable. SAB-185 was being evaluated as part o...

NIH is closing enrollment in its ACTIV-2 trial due to low Omicron-related COVID-19 hospitalization and death rates that have made the current study design statistically unworkable SAB-185 had advanced into Phase 3 after meeting pre-specified efficacy and safety criteria SA...

In the FDA-conducted study , SAB-185 consistently demonstrated high avidity and high potency for effectively neutralizing a broad range of SARS-CoV-2 strains and variants through Delta SAB-185 additionally outperformed convalescent plasma Findings published in The Jo...

SAB Biotherapeutics (NASDAQ:SABS) updated the design of its ongoing phase 3 ACTIV-2 trial evaluating SAB-185 to treat people with mild-moderate COVID infections at higher risk for progression to hospitalization. The Phase 3 trial had been designed as non-inferiority study comparing SAB-185 to...

ACTIV-2 Phase 3 trial continuing as placebo-controlled study in Omicron variant COVID participants SIOUX FALLS, S.D., Feb. 25, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SAB) (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that pro...

SAB-185 is being evaluated in Phase 3 NIH-Sponsored ACTIV-2 COVID trial of high-risk patients following positive DSMB review of interim Phase 2 safety and efficacy data in September More than 700 patients have been enrolled in the Phase 3 trial, exceeding 50% enrollment ...

SIOUX FALLS, S.D., Jan. 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human dono...

SIOUX FALLS, S.D., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, tod...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re getting right into the swing of things with a breakdown of the biggest pre-market stock movers for Thursday! Source: Shutterstock We’ve got an FDA update, several agreements...

SAB Biotherapeutics (NASDAQ:SABS) soars 19% premarket after announcing data, demonstrating that SAB-185, a therapeutic candidate for the treatment of COVID-19 infections, retains neutralization activity against the Omicron SARS-CoV-2 variant in an in vitro pseudovirus model. The res...